Last update 01 Nov 2024
Nesuparib
Last update 01 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms + [4] |
Target |
Mechanism PARP inhibitors(Poly (ADP-Ribose) polymerase inhibitors), TNKS1 inhibitors(tankyrase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC23H24N6O |
InChIKeyGRPXLKXGJAGYSD-UHFFFAOYSA-N |
CAS Registry2055357-64-5 |
Related
5
Clinical Trials associated with NesuparibPhase 2 Study of First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer
Phase 2 study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab with or without Nesuparib, in patients with newly diagnosed advanced or recurrent MMR-proficient (pMMR) endometrial cancer
A Multicenter, Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of JPI-547, a PARP/TNKS Dual Inhibitor in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor
100 Clinical Results associated with Nesuparib
Login to view more data
100 Translational Medicine associated with Nesuparib
Login to view more data
100 Patents (Medical) associated with Nesuparib
Login to view more data
100 Deals associated with Nesuparib
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 3 | KR | 06 Dec 2017 | |
| Advanced Malignant Solid Neoplasm | Phase 3 | KR | 06 Dec 2017 | |
| Recurrent Endometrial Cancer | Phase 2 | - | 01 Aug 2024 | |
| Platinum-Resistant Ovarian Carcinoma | Phase 2 | KR | 31 Aug 2022 | |
| Pancreatic Cancer | Phase 2 | KR | - | |
| Pancreatic Ductal Adenocarcinoma | Phase 1 | KR | 30 Mar 2022 | |
| Secondary malignant neoplasm of pancreas | Phase 1 | KR | 30 Mar 2022 | |
| Colorectal Cancer | Phase 1 | - | - | |
| Colorectal Cancer | Phase 1 | - | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT04335604 (ASCO2021) Manual  | Phase 1 | 62 | (dose escalation) | (pxkcxhplsz) = psfaihvczc auhubeipnx (tlvvnumxwp ) View more | Positive | 20 May 2021 | |
(dose escalation) | (nhuffjepra) = ywbzeibift ydlgxdmkdi (vemrnjtdtm ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free